Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 304

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 304
---
 date). Each of the other representations and warranties of Merger Sub contained in the Business Combination Agreement (disregarding any qualifications or exceptions contained therein relating to materiality, “material” or “material adverse effect” or any similar qualification or exception), shall be true and correct in all respects at and as of the Closing Date as if made at the Closing Date (except with respect to such other representations and warranties which speak as to an earlier date, which representations and warranties, shall be true and correct in all respects at and as of such date), except for inaccuracies in or the failure of such representations and warranties to be true and correct in all respects that, individually or in the aggregate, would not reasonably be excepted to have a material adverse effect on Merger Sub; •each of the agreements and covenants of the Company and Merger Sub under the Business Combination Agreement that are required to be performed as of or prior to the Closing shall have been performed or complied in all material respects; 150 •no Company Material Adverse Effect shall have occurred between the date of the Business Combination Agreement and the Merger Effective Time; •evidence, satisfactory to SPAC, that the Restructuring has occurred pursuant to documentation acceptable to SPAC in accordance with the step plan set forth on Section 8.12 of the Company Disclosure Letter; •counterpart signatures to the Registration Rights and Lock -upAgreement, duly executed by the Company, Parent, the shareholders of Parent specified therein, Theo, CIBIC and those other Persons specified therein (other than SPAC, Sponsor and any shareholder of SPAC); •counterpart signatures to the Assignment, Assumption and Amendment Agreement, duly executed by the Company; and •the Company shall have immediately prior to the Merger Effective Time no more than 30,000,000 issued and outstanding Company Shares (on a fully diluted basis after consummation of the Restructuring), in addition to any Company Shares issued pursuant to the PIPE Subscription Agreements and the Backstop Agreement. Unless waived by the Company in writing, the obligations of the Merger Sub and Company to consummate, or cause to be consummated, the Transactions (including the Merger) at Closing is also subject to the satisfaction of each of the following conditions: •the SPAC Fundamental Representations shall be true and correct in all respects at and as of the Closing Date as if made at and as of the Closing Date (except with respect to such representations and warranties which speak as to an earlier date, which